Trichomonas Vaginitis Global Clinical Trials Review, H2, 2016 – Analysis, Technologies & Forecasts Report – Vendors: Bayer, AmVac, Lumavita – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Trichomonas
Vaginitis Global Clinical Trials Review, H2, 2016″ clinical
trials to their offering.

The clinical trial report “Trichomonas Vaginitis Global Clinical Trials
Review, H2, 2016″ provides an overview of Trichomonas Vaginitis clinical
trials scenario. This report provides top line data relating to the
clinical trials on Trichomonas Vaginitis. Report includes an overview of
trial numbers and their average enrollment in top countries conducted
across the globe.

The report offers coverage of disease clinical trials by region, country
(G7 & E7), phase, trial status, end points status and sponsor type.
Report also provides prominent drugs for in-progress trials (based on
number of ongoing trials).

Scope:

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by
  Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and
  End point status
• The report reviews top companies involved and enlists all trials
  (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated,
  Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to buy:

• Assists in formulating key business strategies with regards to
  investment
• Helps in identifying prominent locations for conducting clinical
  trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which
  helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by
  country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing
  a comparative scenario of completed and uncompleted (terminated,
  suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global,
  regional and country level

Companies Mentioned:

• Altasciences Company Inc
• Endo International Plc
• Bayer AG
• AmVac AG
• Resilient Cosmeceuticals Pvt. Ltd
• Novum Pharmaceutical Research Services, Inc.
• Lumavita AG
• Hikma Pharmaceuticals Plc
• Exeltis Pharmaceuticals Holding SL

For more information about this clinical trials report visit http://www.researchandmarkets.com/research/vdsbm2/trichomonas

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Women’s
Health, Clinical
Trials